Our report provides the subtype specific prevalent population i.e. Focal Epilepsy, Generalized Epilepsy and Unclassified Epilepsy. In addition, the report also covers the prevalent cases of TSC associated Epilepsy in 6MM (excluding Japan). United States contributes the major share of Epilepsy market as compared to EU5 countries and Japan. The therapeutic market of Epilepsy in 7MM is expected to reach USD 8.8 Billion in 2025 at the good CAGR value from 2015-2025. High prevalent cases were observed in United States as compared to EU5 and Japan.
The Report covers the therapeutics market revenue, treatment practice / algorithm and forecasted market size of Epilepsy from 2017 to 2025 segmented by seven major markets. In addition, the report includes the forecasted epidemiology of Epilepsy till 2025.The Report also covers market drivers, market barriers and unmet medical need.
The market is dominated by approved therapies that are used for the treatment of Epilepsy. The three best selling drugs of 2016 were Vimpat (UCB), Lamictal (Glaxosmithkline) and Keppra (UCB).
In the end, Epilepsy Market Insights, Epidemiology and Market Forecast-2025 report provides an overview of the Epilepsy, epidemiology and market trend of the Epilepsy for the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
Key Coverage and Benefits: The report will help in developing business strategies by understanding the trends shaping and driving the Epilepsy market in 7MM. Organize sales and marketing efforts by identifying the best opportunities for Epilepsy in US, European Union 5 (Germany, Spain, Italy, France and United Kingdom) and Japan. To understand the future competition in the Epilepsy market (7MM) and Insightful review of the key market drivers and barriers. The report provides historical as well as forecasted epidemiology of Epilepsy in the 7MM covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025. The Report also covers the detailed historical and forecasted Epilepsy market covering United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom), Japan and Rest of the World (RoW) from 2015-2025.
Global Epilepsy Market Report 2017 1. Report Summary 2. Epilepsy Disease Background 3. Epidemiology and Patient Population 4. Prevalence of Epilepsy in United States, Germany, France, Italy, Spain, United Kingdom and Japan 5. Gender specific prevalence in United States, Germany, France, Italy, Spain, United Kingdom and Japan 6 Sub-type specific prevalence in United States, Germany, France, Italy, Spain, United Kingdom and Japan 7. Treatment Algorithm 8. Unmet Needs 9. Competitive Landscape-Marketed Drugs 10. Emerging Therapies 11. Epidiolex: GW Pharmaceuticals 12. Fintepla: Zogenix 13. PF-06372865: Pfizer 14. UCB0942: UCB 15. Ganaxolone: Marinus Pharmaceuticals 16. SAGE-547: Sage Therapeutics 17. Triheptanoin: Ultragenyx Pharmaceutical 18. CPP-115: Catalyst Pharmaceuticals 19. ZYN002: Zynerba Pharma 20. Market Size of Epilepsy 21. Global Market Size 22. Market Drivers 23. Market Barriers 24. Appendix
About us: Precise market reports, a one-stop research platform designed to help key decision makers and dynamic thought leaders across various industry verticals worldwide by making them aware of the past, current and future market scenario. Tier 1's, SME's startups, top management consultants, have clearly visualized their environment using our analysis, thus enabling them to make critical business decisions and in devising a strategic plan.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
